Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Consumption of dairy products is beneficial to human health, with a recent study reporting that high intake levels are associated with reduced risks of type 2 diabetes and cardiovascular disease (CVD) among women.
Men and women enjoy equal survival benefits from chronic total coronary occlusion percutaneous coronary intervention (PCI), reports a new study.
Persistent high residual inflammatory risk (RIR) is frequent in patients undergoing percutaneous coronary intervention (PCI) with baseline low-density lipoprotein cholesterol (LDL-C) ≤70 mg/dl and appears to increase the risk of major adverse cardiac and cerebrovascular event (MACCE; ie, death, myocardial infarction or stroke), a recent study has shown.
A recent study has shown an association between regular use of glucosamine supplement to relieve osteoarthritis pain and lower risk of cardiovascular disease (CVD) events.
Increased consumption of salt appears to reduce sublingual microvascular density following administration of nitroglycerin (NTG), according to a recent study, adding that larger changes in body weight following high salt intake coincide with a larger decrease in microvascular density.
Patients at a more advanced stage of chronic kidney disease (CKD) are highly likely to discontinue treatment with commonly used blood pressure-lowering drugs, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), a study has found.
There appears to be an inverse association between serum phosphate levels and the risk of developing hyperuricaemia among adult patients with hypertension, a study has found.
Special Reports
At the recent 12th IDF-WPR Congress and 10th AASD Scientific Meeting held at Kuala Lumpur Convention Centre, the importance of glycaemic control and the practical management of type 2 diabetes mellitus (T2DM) were highlighted by two international speakers, Dr Sanjay Kalra from India and Professor Jean Claude Mbanya from Cameroon.
At a webinar hosted by Pfizer, leading Malaysian family medicine specialists Professor Chia Yook Chin andProfessor Sherina Mohd Sidik discussed a host of issues commonly encountered in primary care, includingpreventing cardiovascular (CV) disease, pain control in osteoarthritis (OA) and depression management.
Coronary artery disease (CAD) is a leading cause of mortality and morbidity globally and its burden is expected to increase due to the rising prevalence of risk factors such as hypertension, diabetes, and dyslipidaemia. In conjunction with the 23rd ASEAN Federation of Cardiology Congress held in Bangkok, Thailand, Menarini organized a lunch symposium and product theatre to discuss the significance of optimal medical therapy (OMT) in the management of stable CAD, with a focus on the role of ranolazine (Ranexa®).
Despite risk factors for cardiovascular disease (CVD) being similar around the world, the burden of CVD is not uniform across nations. Furthermore, CVD-related death in low- to middle-income countries (LMICs) has increased by two-thirds in the last 30 years, and now account for a whopping 80% of global deaths due to CVD.
Poor adherence to statin therapy is leaving many patients with dyslipidaemia at high risk of potentially life-threatening cardiovascular events. Statins are the current standard of care for reducing the risk of cardiovascular disease in these patients and for improving life expectancy, with possible economic benefits for healthcare systems too. However, many patients with dyslipidaemia are not achieving or maintaining treatment targets because they fail to stick to their prescribed statin therapy. An article co-authored by lipidologist Peter Lansberg, and published in Vascular Health and Risk Management, considers this issue and reviews approaches to overcome non-adherence.
At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.
Through a cardiology webcast co-hosted by Pfizer, the National Heart Association of Malaysia (NHAM), and the American College of Cardiology (ACC), Dr Ong Mei Lin, Dr Aaron D. Kugelmass and Dr Tracy Wang shared their insights into the importance of secondary prevention measures in reducing the burden of atherosclerotic cardiovascular disease (ASCVD).
Conference Reports
Foregoing intracardiac electrophysiologic mapping was as good as conventional cryoablation with pulmonary vein (PV) mapping in the AVATAR-HF* study, suggesting that a simplified procedure could produce the same outcomes for lower costs.
Systolic blood pressure (SBP) above 129 mm Hg was associated with an increased risk of dementia in middle-aged patients with atrial fibrillation (AF), according to a study presented at EHRA 2019.
Use of uninterrupted edoxaban during catheter ablation for atrial fibrillation (AF) shows comparable safety and efficacy as uninterrupted vitamin K antagonists (VKAs), according to the ELIMINATE-AF trial presented at EHRA 2019.
Patients on the anticoagulant drug edoxaban could safely continue their treatment while undergoing certain procedures, with a low incidence of bleeding and cardiovascular events reported in the prospective EMIT AF/VTE* study.
Remote monitoring (RM) reduced hospitalization rates in patients with heart failure (HF) and implanted cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D), according to data from the RESULT* trial presented at EHRA 2019.
The use of catheter ablation as first-line treatment reduces the number of premature ventricular complexes (PVCs) in a paediatric population, according to a study presented at EHRA 2019.
Patients who have recently experienced atrial fibrillation (AF) could benefit from treatment with upfront rate-control medication rather than undergoing immediate cardioversion to restore sinus rhythm, according to The Netherlands-based RACE 7 ACWAS* trial.
Multimedia
